Specialty pharmaceutical company Supernus Pharmaceuticals is set to launch once-daily extended release formulation of topiramate, Trokendi XR, to treat epilepsy following the final FDA approval.
Takeda Pharmaceutical Company has announced the availability of NESINA (alogliptin) and fixed-dose combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) by prescription in the US.
Eisai has announced the availability of Belviq (lorcaserin HCl) CIV tablets in the US, which is designed for chronic weight management in adults who are overweight with a comorbidity or obesity.
Second Genome has signed a microbiome drug discovery deal with Janssen Biotech to advance novel drug targets mediated by the bacterial ecosystem living within the human gut to treat ulcerative colitis.
Amedra Pharmaceuticals has re-launched a single-dose epinephrine auto-injector Adrenaclick for people with increased risk of anaphylaxis in both 0.15mg and 0.30mg strengths.
Johnson & Johnson (J&J) Innovation has opened the new California Innovation Center to build early stage collaborations with emerging companies in science and technology and advance healthcare.
The USPTO has issued a notice of allowance for GW Pharmaceuticals' patent application regarding Sativex formulation spray device.